Vaccination against human papillomavirus (HPV) after allogeneic stem cell transplantation, a randomized study between early and late vaccination.

Conditions

Recipients of allogeneic stem cell transplantation

Brief summary

Antibody level (GMT) against HPV 16 measured 1 months after the third vaccine dose, early vs late

Detailed description

Antibody level (GMT) against all 9 HPV-serotypes included in vaccine (-6, -11, -16, -18, -31, -33, -45, -52, -58) measured 1 month after the third vaccinedose. Early vs late., Antibody level (GMT) against all 9 HPV-serotypes included in vaccine (-6, -11, -16, -18, -31, -33, -45, -52, -58) measured at 12 months after the third vaccine dose. Early vs late., Proportion seropositive/negative against 9 HPV-serotypes included in vaccine measured 1 and 12 months after third dose. Early vs late., Seroconversion against 9 HPV-serotypes included in vaccine, prevaccination compared to 1 month after third dose, early vs late., Proportion seropositive against 7/9 HPV-types included in the vaccine at 1 and 12 months after completion of vaccination. Early vs late.

Related papers

No related papers found yet.

Interventions

DRUGGardasil 9 suspension for injection. Human Papillomavirus 9-valent Vaccine (Recombinant

DRUGadsorbed)

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Antibody level (GMT) against HPV 16 measured 1 months after the third vaccine dose, early vs late	—

Secondary

Measure	Time frame
Antibody level (GMT) against all 9 HPV-serotypes included in vaccine (-6, -11, -16, -18, -31, -33, -45, -52, -58) measured 1 month after the third vaccinedose. Early vs late., Antibody level (GMT) against all 9 HPV-serotypes included in vaccine (-6, -11, -16, -18, -31, -33, -45, -52, -58) measured at 12 months after the third vaccine dose. Early vs late., Proportion seropositive/negative against 9 HPV-serotypes included in vaccine measured 1 and 12 months after third dose. Early vs late., Seroconversion against 9 HPV-serotypes included in vaccine, prevaccination compared to 1 month after third dose, early vs late., Proportion seropositive against 7/9 HPV-types included in the vaccine at 1 and 12 months after completion of vaccination. Early vs late.	—

Measure

Time frame

Antibody level (GMT) against all 9 HPV-serotypes included in vaccine (-6, -11, -16, -18, -31, -33, -45, -52, -58) measured 1 month after the third vaccinedose. Early vs late., Antibody level (GMT) against all 9 HPV-serotypes included in vaccine (-6, -11, -16, -18, -31, -33, -45, -52, -58) measured at 12 months after the third vaccine dose. Early vs late., Proportion seropositive/negative against 9 HPV-serotypes included in vaccine measured 1 and 12 months after third dose. Early vs late., Seroconversion against 9 HPV-serotypes included in vaccine, prevaccination compared to 1 month after third dose, early vs late., Proportion seropositive against 7/9 HPV-types included in the vaccine at 1 and 12 months after completion of vaccination. Early vs late.

—

Countries

Sweden

Outcome results

None listed